Medication used to treat tuberculosis
Bedaquiline Trade names Sirturo Other names Bedaquiline fumarate,[ 1] TMC207,[ 2] R207910, AIDS222089 AHFS /Drugs.com Monograph MedlinePlus a613022 License data
Routes of administration By mouth ATC code Legal status
Protein binding >99.9%[ 6] Metabolism Liver, by CYP3A4 [ 7] Elimination half-life 5.5 months[ 7] Excretion fecal[ 7]
(1R ,2S )-1-(6-Bromo-2-methoxy-3-quinolyl)-4-dimethylamino-2-(1-naphthyl)-1-phenylbutan-2-ol
CAS Number PubChem CID DrugBank ChemSpider UNII KEGG ChEBI ChEMBL CompTox Dashboard (EPA ) Formula C 32 H 31 Br N 2 O 2 Molar mass 555.516 g·mol−1 3D model (JSmol )
Brc1ccc2nc(OC)c(cc2c1)[C@@H](c3ccccc3)[C@](O)(c5c4ccccc4ccc5)CCN(C)C
InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1
Key:QUIJNHUBAXPXFS-XLJNKUFUSA-N
Bedaquiline , sold under the brand name Sirturo , is a medication used for the treatment of active tuberculosis .[ 1] Specifically, it is used to treat multi-drug-resistant tuberculosis along with other medications for tuberculosis .[ 1] [ 8] [ 9] It is taken by mouth .[ 3]
Common side effects include nausea, joint pains , headaches, and chest pain.[ 1] Serious side effects include QT prolongation , liver dysfunction, and an increased risk of death.[ 1] While harm during pregnancy has not been found, it has not been well studied in this population.[ 10] It is in the diarylquinoline antimycobacterial class of medications.[ 1] It works by blocking the ability of M. tuberculosis to make adenosine 5'-triphosphate (ATP).[ 1]
Bedaquiline was approved for medical use in the United States in 2012.[ 1] It is on the World Health Organization's List of Essential Medicines .[ 11]
^ a b c d e f g h "Bedaquiline Fumarate" . The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016 .
^ Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. (June 2009). "The diarylquinoline TMC207 for multidrug-resistant tuberculosis" . The New England Journal of Medicine . 360 (23): 2397–405. doi :10.1056/NEJMoa0808427 . PMID 19494215 .
^ a b "Sirturo- bedaquiline fumarate tablet" . DailyMed . 17 October 2023. Archived from the original on 19 April 2024. Retrieved 20 April 2024 .
^ "Sirturo EPAR" . European Medicines Agency . 26 August 2005. Archived from the original on 18 March 2024. Retrieved 18 March 2024 .
^ "Sirturo Product information" . Union Register of medicinal products . 7 March 2014. Archived from the original on 18 March 2024. Retrieved 18 March 2024 .
^ "Sirturo: Clinical Pharmacology" . Archived from the original on 28 February 2015. Retrieved 28 April 2014 .
^ a b c "Bedaquiline" . Archived from the original on 20 May 2013. Retrieved 28 April 2014 .
^ "WHO Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)" . World Health Organization (WHO) . Archived from the original on 20 August 2018. Retrieved 24 April 2019 .
^ Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, et al. (Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017) (September 2018). "Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis" . Lancet . 392 (10150): 821–834. doi :10.1016/S0140-6736(18)31644-1 . PMC 6463280 . PMID 30215381 .
^ "Bedaquiline (Sirturo) Use During Pregnancy" . www.drugs.com . Archived from the original on 20 December 2016. Retrieved 10 December 2016 .
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) . Geneva: World Health Organization. hdl :10665/371090 . WHO/MHP/HPS/EML/2023.02.